HighTower Advisors
BDSX icon

HighTower Advisors’s Biodesix BDSX Stock Holding History

HighTower Advisors’s Portfolio BDSX Stock Details BDSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-7,963
Closed -$44.9K – 3840
2025
Q2 		$44.9K Buy
7,963
+166
+2% +$1.34K ﹤0.01% 3556
2025
Q1 		$97.5K Buy
7,797
+100
+1% +$1.92K ﹤0.01% 3364
2024
Q4 		$236K Buy
7,697
+1,125
+17% +$33.1K ﹤0.01% 3075
2024
Q3 		$234K Hold
6,572
– – ﹤0.01% 3012
2024
Q2 		$202K Hold
6,572
– – ﹤0.01% 3017
2024
Q1 		$188K Hold
6,572
– – ﹤0.01% 3004
2023
Q4 		$242K Sell
6,572
-250
-4% -$7.85K ﹤0.01% 2875
2023
Q3 		$225K Hold
6,822
– – ﹤0.01% 2821
2023
Q2 		$167K Hold
6,822
– – ﹤0.01% 2933
2023
Q1 		$254K Hold
6,822
– – ﹤0.01% 2572
2022
Q4 		$314K Buy
+6,822
New +$185K ﹤0.01% 2432

Other funds holding BDSX

TAM
Telemark Asset Management Boston, Massachusetts $1.08B AUM 70.88% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HighTower Advisors's BDSX Position: Q3 2025 in Review

HighTower Advisors sold out of Biodesix (BDSX) in Q3 2025, closing a stake of 7,963 shares — an estimated $44.9K sold.

HighTower Advisors first reported a position in BDSX in Q4 2022 and held it in 11 quarters. The position peaked at $314K in Q4 2022. 26 funds tracked by Wall St. Rank hold BDSX as of Q3 2025.

  • HighTower Advisors reported no remaining Biodesix position as of Q3 2025 after selling out during the quarter.
  • HighTower Advisors sold 7,963 Biodesix shares in Q3 2025, an estimated $44.9K.
  • HighTower Advisors first reported a position in Biodesix in Q4 2022 and held it in 11 quarters.
  • HighTower Advisors's Biodesix position peaked at $314K in Q4 2022.
  • 26 funds tracked by Wall St. Rank held Biodesix as of Q3 2025.

Based on HighTower Advisors's 13F filing for Q3 2025, filed 7 Nov 2025.